Filing Flows › Vivos Therapeutics (VVOS) › Q1 2026 › vs Q1 2025
Vivos Therapeutics (VVOS) Q1 2026 vs Q1 2025 (year over year)
Vivos Therapeutics's revenue rose $2.1M (+70%) from $3.0M in Q1 2025 to $5.1M in Q1 2026. The biggest changes: Service +$2.1M (+132%).
Vivos Therapeutics, Q1 2026: revenue $5.1M (+70% year over year), operating margin -128.7%, net loss $7.8M, operating cash flow −$6.0M. The chart draws each line against Q1 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q1 2025 | Change | % |
|---|---|---|---|---|
| Sleep Testing Services | $2.3M | $323K | $2.0M | +611% |
| Tooth Positioners | $1.0M | $540K | $478K | +89% |
| Appliances | $422K | $1.3M | −$851K | -67% |
| Sponsorship Seminar Other | $205K | $328K | −$123K | -38% |
| Billing Intelligence Services | $145K | $181K | −$36K | -20% |
| Myofunctional Therapy Services | $125K | $148K | −$23K | -16% |
| VIP | $37K | $223K | −$186K | -83% |
| Service | $3.7M | $1.6M | $2.1M | +132% |
| Revenue | $5.1M | $3.0M | $2.1M | +70% |
| Net loss | $7.8M | $3.9M | $3.9M | +101% |
| Costs & expenses | $12.9M | $6.9M | $6.0M | +86% |
| Operating costs | $11.8M | $6.9M | $4.8M | +70% |
| Interest & other, net | $1.1M | −$54K | $1.2M | — |
| Cost of revenue | $2.1M | $1.5M | $575K | +38% |
| Sales & marketing | $249K | $358K | −$109K | -30% |
| General & admin | $9.0M | $4.9M | $4.1M | +83% |
| Other operating costs | $454K | $177K | $277K | +156% |
| Operating cash sources | $7.8M | $3.9M | $3.9M | +101% |
| Depreciation & amortization | $454K | $177K | $277K | +156% |
| Share-based compensation | $151K | $317K | −$166K | -52% |
| Working capital & other | $1.1M | −$426K | $1.6M | — |
| Cash used in operations | $6.0M | $3.8M | $2.2M | +58% |
| Net loss absorbed | $7.8M | $3.9M | $3.9M | +101% |
Questions
How much did Vivos Therapeutics's revenue grow year over year in Q1 2026?
Vivos Therapeutics's revenue rose $2.1M (+70%) from $3.0M in Q1 2025 to $5.1M in Q1 2026.
What drove Vivos Therapeutics's revenue change in Q1 2026?
Service +$2.1M (+132%).